Thursday, October 15, 2026

Copper Bullish Momentum: 0.76% Up Since The Last Session

ViaNews Editorial Team

January 18, 2021

Copper Bullish Momentum: 0.76% Up Since The Last Session

Copper is currently on bullish momentum. At 06:00 EST on Monday, 18 January, Copper is at $3.63 and 0.76% up since the last session's close.

Copper Range

Copper is 1.199% up from its last session low of $3.59 and 1.479% down from its last session high of $3.68.

Copper is 1.48% down from its last three sessions higher value of $3.68 and is 1.20% up from its last three sessions lower value of $3.59.

Copper is 2.80% down from its last seven sessions higher value of $3.73 and is 2.04% up from its last seven sessions lower value of $3.56.

Copper is 2.80% down from its last month's higher value of $3.73 and is 3.54% up from its last month's lower value of $3.51.

Volatility

Copper's last day, last week, and last month's average volatility was a negative 1.86%, a negative 0.20%, and a positive 0.20%, respectively.

Copper's last day, last week, and last month's high and low average amplitude percentage was 2.72%, 0.78%, and 0.65%, respectively.

Last news about Copper

Rio tinto seeks to ease tension over Arizona copper mine project. According to Bloomberg Quint on Friday, 15 January, "Like the rock shelters at Juukan Gorge, Oak Flat is a sacred and holy place that Resolution Copper greedily seeks," Rambler said last year in a letter to a committee of Australian lawmakers. ", "The project manager of Rio's Resolution Copper wrote to 11 Native American tribes last month, saying the company welcomed the opportunity to increase direct engagement with the groups, while emphasizing that the development remains in the early stages."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com